Search
Displaying 121–130 of 694 for “retinal diseases”
-
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Research NewsKnown as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
RP Treatment Derived from Induced Pluripotent Stem Cells Advances into Clinical Trial
Research NewsThe stem cells were derived from mature blood cells and coaxed to become photoreceptors
-
FFB Provides Four Career Development Awards to Up-and-Coming Clinical Researchers
Research NewsEach recipient will receive a total of $375,000 over five years to help build an independent research program in addition to their clinical practices.
-
Is Acupuncture a Beneficial Treatment for Retinitis Pigmentosa?
Research NewsAcupuncture definitely has potential benefits, and the breadth of those is being aggressively explored.
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Foundation News
The free, online event at 7 p.m. ET on Tuesday, November 11, 2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
Career Development Program (CDA)
Objective/Goal: The goal of this Program is to facilitate advances in laboratory and clinical research, to elucidate the mechanisms for the etiology and pathogenesis of retinal degenerative diseases and to develop innovative strategies to prevent, treat and cure these diseases. This program supports up to five junior-level faculty for five (5) years. $75,000/year
